- Home
- PLX vs NMT Comparison
PLX vs NMT Comparison
Compare PLX & NMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- NMT
- Stock Information
- Founded
- PLX 1993
- NMT 1993
- Country
- PLX United States
- NMT United States
- Employees
- PLX N/A
- NMT N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- NMT Finance/Investors Services
- Sector
- PLX Health Care
- NMT Finance
- Exchange
- PLX Nasdaq
- NMT Nasdaq
- Market Cap
- PLX 122.6M
- NMT 109.8M
- IPO Year
- PLX 1998
- NMT N/A
- Fundamental
- Price
- PLX $1.46
- NMT $11.59
- Analyst Decision
- PLX Strong Buy
- NMT
- Analyst Count
- PLX 1
- NMT 0
- Target Price
- PLX $15.00
- NMT N/A
- AVG Volume (30 Days)
- PLX 1.3M
- NMT 19.1K
- Earning Date
- PLX 08-13-2025
- NMT 01-01-0001
- Dividend Yield
- PLX N/A
- NMT 3.21%
- EPS Growth
- PLX N/A
- NMT N/A
- EPS
- PLX 0.05
- NMT N/A
- Revenue
- PLX $59,764,000.00
- NMT N/A
- Revenue This Year
- PLX $65.02
- NMT N/A
- Revenue Next Year
- PLX $57.34
- NMT N/A
- P/E Ratio
- PLX $30.21
- NMT N/A
- Revenue Growth
- PLX 0.18
- NMT N/A
- 52 Week Low
- PLX $0.82
- NMT $9.05
- 52 Week High
- PLX $3.10
- NMT $10.93
- Technical
- Relative Strength Index (RSI)
- PLX 46.02
- NMT 38.58
- Support Level
- PLX $1.36
- NMT $11.61
- Resistance Level
- PLX $1.54
- NMT $11.88
- Average True Range (ATR)
- PLX 0.08
- NMT 0.10
- MACD
- PLX 0.02
- NMT -0.01
- Stochastic Oscillator
- PLX 41.67
- NMT 4.84
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.